Champions Oncology, Inc. (FRA:2I3)
Germany · Delayed Price · Currency is EUR 5.85
+0.65 (12.50%)
At close: Dec 19, 2025
Champions Oncology Income Statement
Financials in millions USD. Fiscal year is May - April.
Millions USD. Fiscal year is May - Apr.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Oct '25 Oct 31, 2025 | Apr '25 Apr 30, 2025 | Apr '24 Apr 30, 2024 | Apr '23 Apr 30, 2023 | Apr '22 Apr 30, 2022 | Apr '21 Apr 30, 2021 | 2016 - 2020 |
| 58.42 | 56.94 | 50.16 | 53.87 | 49.11 | 41.04 | Upgrade | |
Revenue Growth (YoY) | 9.06% | 13.54% | -6.90% | 9.70% | 19.66% | 27.76% | Upgrade |
Cost of Revenue | 29.15 | 28.39 | 29.4 | 29.53 | 23.63 | 21.45 | Upgrade |
Gross Profit | 29.28 | 28.56 | 20.75 | 24.34 | 25.48 | 19.59 | Upgrade |
Selling, General & Admin | 18.44 | 16.88 | 18.13 | 17.24 | 15.5 | 12.03 | Upgrade |
Research & Development | 8.38 | 6.83 | 9.54 | 11.55 | 9.37 | 7.2 | Upgrade |
Operating Expenses | 26.82 | 23.71 | 27.68 | 28.79 | 24.87 | 19.23 | Upgrade |
Operating Income | 2.46 | 4.85 | -6.92 | -4.45 | 0.61 | 0.37 | Upgrade |
Interest Expense | -0.03 | -0.03 | -0.03 | - | - | - | Upgrade |
Interest & Investment Income | 0.09 | 0.09 | 0.09 | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | 0.01 | 0.01 | -0.02 | -0.01 | -0.02 | -0.01 | Upgrade |
Other Non Operating Income (Expenses) | 0.14 | 0 | - | - | - | - | Upgrade |
EBT Excluding Unusual Items | 2.67 | 4.92 | -6.87 | -4.46 | 0.58 | 0.36 | Upgrade |
Gain (Loss) on Sale of Assets | -0.31 | -0.29 | -0.44 | - | - | - | Upgrade |
Asset Writedown | - | - | - | -0.81 | - | - | Upgrade |
Other Unusual Items | - | - | - | - | - | 0.08 | Upgrade |
Pretax Income | 2.36 | 4.63 | -7.31 | -5.27 | 0.58 | 0.44 | Upgrade |
Income Tax Expense | -0.07 | -0.08 | -0.03 | 0.07 | 0.04 | 0.08 | Upgrade |
Net Income | 2.49 | 4.7 | -7.28 | -5.34 | 0.55 | 0.36 | Upgrade |
Net Income to Common | 2.49 | 4.7 | -7.28 | -5.34 | 0.55 | 0.36 | Upgrade |
Net Income Growth | - | - | - | - | 51.38% | - | Upgrade |
Shares Outstanding (Basic) | 14 | 14 | 14 | 14 | 13 | 13 | Upgrade |
Shares Outstanding (Diluted) | 14 | 14 | 14 | 14 | 14 | 15 | Upgrade |
Shares Change (YoY) | 4.06% | 5.31% | 0.04% | -4.37% | -2.84% | 23.05% | Upgrade |
EPS (Basic) | 0.18 | 0.34 | -0.54 | -0.39 | 0.04 | 0.03 | Upgrade |
EPS (Diluted) | 0.17 | 0.33 | -0.54 | -0.39 | 0.04 | 0.02 | Upgrade |
EPS Growth | - | - | - | - | 100.01% | - | Upgrade |
Free Cash Flow | 5.64 | 7 | -6.97 | 1.1 | 4.11 | -4.96 | Upgrade |
Free Cash Flow Per Share | 0.40 | 0.49 | -0.52 | 0.08 | 0.29 | -0.34 | Upgrade |
Gross Margin | 50.11% | 50.15% | 41.38% | 45.18% | 51.88% | 47.74% | Upgrade |
Operating Margin | 4.22% | 8.51% | -13.80% | -8.26% | 1.24% | 0.89% | Upgrade |
Profit Margin | 4.26% | 8.25% | -14.51% | -9.90% | 1.12% | 0.88% | Upgrade |
Free Cash Flow Margin | 9.65% | 12.29% | -13.90% | 2.04% | 8.38% | -12.09% | Upgrade |
EBITDA | 3.97 | 6.49 | -5.05 | -2.83 | 2.23 | 1.55 | Upgrade |
EBITDA Margin | 6.79% | 11.39% | -10.08% | -5.26% | 4.55% | 3.78% | Upgrade |
D&A For EBITDA | 1.51 | 1.64 | 1.87 | 1.62 | 1.63 | 1.18 | Upgrade |
EBIT | 2.46 | 4.85 | -6.92 | -4.45 | 0.61 | 0.37 | Upgrade |
EBIT Margin | 4.22% | 8.51% | -13.80% | -8.26% | 1.24% | 0.89% | Upgrade |
Effective Tax Rate | - | - | - | - | 6.00% | 17.16% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.